CSF Biomarkers of Alzheimer’s Disease : Impact on Disease Concept, Diagnosis, and Clinical Trial Design
المؤلف
المصدر
العدد
المجلد 2014، العدد 2014 (31 ديسمبر/كانون الأول 2014)، ص ص. 1-14، 14ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2014-08-14
دولة النشر
مصر
عدد الصفحات
14
التخصصات الرئيسية
الملخص EN
Data from clinicopathologic and biomarker studies have converged to support the view of Alzheimer’s disease (AD) as a continuum, with pathology developing decades prior to the onset of cognitive symptoms which culminate as dementia at the end stage of the disease.
This concept is impacting disease nomenclature, diagnostic criteria, prognostic potential, and clinical trial design.
Revisions to diagnostic criteria to incorporate biomarker results have recently been proposed in order to increase the confidence of AD as the underlying etiology of a clinical impairment and to permit a diagnosis of AD across the disease continuum, eventually perhaps in the asymptomatic period.
Individuals in this preclinical stage are receiving intense focus as a targeted population for secondary prevention trials aimed at identifying disease-modifying therapies that have the best chance of preserving normal cognitive function.
The goal is to bring validated biomarkers to clinical practice for the purpose of disease diagnosis, prognosis, and evaluation of therapeutic efficacy once disease-modifying treatments become available.
Realization of this goal requires worldwide biomarker standardization efforts, consensus among researchers and clinicians regarding the clinical utility of assessing biomarkers in patient care settings, and eventually the endorsement and adoption of such procedures and practices into global health care systems.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Fagan, Anne M.. 2014. CSF Biomarkers of Alzheimer’s Disease : Impact on Disease Concept, Diagnosis, and Clinical Trial Design. Advances in Geriatrics،Vol. 2014, no. 2014, pp.1-14.
https://search.emarefa.net/detail/BIM-461721
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Fagan, Anne M.. CSF Biomarkers of Alzheimer’s Disease : Impact on Disease Concept, Diagnosis, and Clinical Trial Design. Advances in Geriatrics No. 2014 (2014), pp.1-14.
https://search.emarefa.net/detail/BIM-461721
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Fagan, Anne M.. CSF Biomarkers of Alzheimer’s Disease : Impact on Disease Concept, Diagnosis, and Clinical Trial Design. Advances in Geriatrics. 2014. Vol. 2014, no. 2014, pp.1-14.
https://search.emarefa.net/detail/BIM-461721
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-461721
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر